Remdesivir + Corticosteroids Boost Survival in COVID-19 Patients With COPD

Early initiation of remdesivir (Veklury, Gilead Sciences) and corticosteroids in patients with COPD and COVID-19 ...

AUGUST 8, 2025

Veklury Appears to Reduce Risk for Long COVID

Remdesivir appears to reduce the risk for certain long COVID-19 symptoms in people who were hospitalized for ...

MARCH 6, 2024

Veklury Reduces Mortality in Immunocompromised People With COVID-19

Veklury can have significant benefits for immunocompromised people with COVID-19, reducing mortality by 30%.

FEBRUARY 14, 2024

FDA Grants New Indication for Veklury to Treat COVID-19 in People With Hepatic Impairment

The FDA granted a supplemental new drug application for the use of remdesivir with no dose adjustments to treat ...

AUGUST 25, 2023

FDA Expands Indication for Veklury to Treat COVID-19 Patients With Renal Impairment

With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across ...

JULY 14, 2023

Remdesivir-Resistant Version of COVID-19 Detected in Organ Transplant Recipients

Two kidney transplant patients treated with immunosuppressive drugs, and who later had a lengthy COVID-19 ...

NOVEMBER 7, 2022

FDA Approves Veklury, First COVID-19 Treatment for Young Children

The FDA expanded the approval of the COVID-19 drug remdesivir (Veklury, Gilead) to include pediatric patients 28 ...

APRIL 26, 2022

Remdesivir Resistance Found in Immunocompromised Patient

Yale researchers said the discovery raised concerns about the emergence of drug resistance in COVID-19 patients, ...

MARCH 23, 2022

FDA Limits Use of Monoclonal Antibodies to Treat COVID-19

The FDA revised the EUAs for two monoclonal antibody cocktails for COVID-19, essentially saying the should not be ...

JANUARY 25, 2022

FDA Expands Use of Veklury for Mild to Moderate COVID-19

Previously limited to hospitalized patients, The FDA expands use of remdesivir to the outpatient setting.

JANUARY 24, 2022